Why are CSL shares falling today?

CSL shareholders may have mixed feelings today.

| More on:
Cropped shot of an attractive young female scientist working on her computer in the laboratory.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The CSL Ltd (ASX: CSL) share price is down 2% in early trading as the ASX healthcare share feels the effects of the ASX stock market sell-off. CSL shares also went ex-dividend today.

On Friday in the US market, there was a sizeable decline in a number of stocks. Nvidia fell 5.5%, Eli Lilly dropped 2.3%, Microsoft declined 0.7%, Tesla fell 1.8% and so on. The S&P/ASX 200 Index (ASX: XJO) is currently down by 1.3%.

Ex-dividend day

One of the factors that may be impacting CSL shares today is that it went ex-dividend.

An ex-dividend date tells the market when new investors buying shares will miss out on the upcoming dividend. There has to be a cut-off point for deciding who will and who won't receive the dividend.

Anyone who buys today is missing out on the interim dividend payment. Investors who bought CSL shares last week are eligible to receive the dividend, assuming they're still shareholders on the record date (tomorrow).

How much is being paid?

CSL is going to pay a dividend of US$1.19 to shareholders, which at the time of the FY24 first-half result translated into approximately A$1.81 per share (an increase of 12%).

At the current exchange rates, the upcoming payment equates to A$1.80 per share.

CSL is expecting to release information about exchange rates for Australian and New Zealand dollar payments on 14 March 2024.

The ASX healthcare share is planning to pay this dividend on 3 April 2024, which is only a few weeks away.

CSL was able to deliver a bigger dividend after growing net profit after tax (NPAT) by 17% to US$1.9 billion in its FY24 first-half result. It also reported underlying earnings per share (EPS) growth of 11% to US$4.18.

Profit expectations

The company is expecting to report underlying NPATA of between US$2.9 billion to US$3 billion, which would be growth of between 13% to 17%.

Management thinks the business is in a strong position to deliver annualised double-digit earnings growth over the medium term.

On Commsec, the estimates imply the CSL share price is currently valued at 30 times FY24's estimated earnings. It could pay an annual dividend of A$4, according to Commsec, which puts the forecast forward dividend yield at 1.4%.

Motley Fool contributor Tristan Harrison has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended CSL, Microsoft, Nvidia, and Tesla. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has recommended the following options: long January 2026 $395 calls on Microsoft and short January 2026 $405 calls on Microsoft. The Motley Fool Australia has recommended CSL and Nvidia. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

Why is everyone talking about ResMed shares?

It’s been a good year for ResMed shareholders. Let’s find out why.

Read more »

Male doctor in a lab coat working at laptop looking serious.
Healthcare Shares

This bombshell for ASX healthcare shares could hit 6 million Australians

This could have a large impact.

Read more »

Two scientists in a Rhythm Biosciences lab cheer while looking at results on a computer.
Healthcare Shares

2 ASX healthcare shares having a stellar run today

The ASX healthcare sector is down today but these two stocks are bucking the trend.

Read more »

A company manager presents the ASX company earnings report to shareholders at an AGM.
Healthcare Shares

Why this $13 billion ASX 200 healthcare stock is surging today

A change in sentiment for the healthcare player.

Read more »

Shot of a scientist using a computer while conducting research in a laboratory.
Healthcare Shares

This ASX 200 stock hit a 52-week low and a top broker thinks it can rebound

Patient investors may see this stock make a pleasing recovery.

Read more »

A couple smile as they look at a pregnancy test.
Healthcare Shares

Why this sold-off ASX healthcare share could be an exciting dividend buy

This could be a healthy stock for dividends.

Read more »

a smiling woman sits at her computer at home with a coffee alongside her, as if pleased with her investments.
Healthcare Shares

Is CSL the best ASX 100 share to buy now?

Bell Potter has good things to say about this blue chip star.

Read more »

Scientists in a laboratory look at a computer screen with anticipation on their faces representing a potential change in the performance of ASX biotech shares in FY23
Healthcare Shares

Down 10% in a month, are CSL shares feeling the sting of a potential disruption?

Brokers are still bullish.

Read more »